Haemolytic uraemic syndrome associated with gemcitabine

Haemolytic uraemic syndrome (HUS) is a rare thromboembolic complication observed in patients with cancer. It is characterised by the clinical triad of acute renal failure, microangiopathic haemolytic anaemia and thrombocytopaenia. It may be associated with a variety of aetiologies, including chemoth...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2010-05, Vol.12 (5), p.381-383
Main Authors: Moya-Horno, Irene, Querol Niñerola, Rosa, Bonfill Abella, Teresa, Dalmau Pórtulas, Elsa, Gallardo-Díaz, Enrique, Saigí Grau, Eugeni, Pericay Pijaume, Carles
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carcinoma - drug therapy
Carcinoma - pathology
Case Reports
Deoxycytidine - administration & dosage
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Hemolytic-Uremic Syndrome - chemically induced
Humans
Male
Medicine
Medicine & Public Health
Oncology
Urinary Bladder Neoplasms - drug therapy
Urinary Bladder Neoplasms - pathology
Urothelium - drug effects
Urothelium - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Haemolytic uraemic syndrome (HUS) is a rare thromboembolic complication observed in patients with cancer. It is characterised by the clinical triad of acute renal failure, microangiopathic haemolytic anaemia and thrombocytopaenia. It may be associated with a variety of aetiologies, including chemotherapeutic agents such as mitomycin, cisplatin, bleomycin, 5-fluorouracil and, most recently, gemcitabine. We report a 70-year-old patient treated with gemcitabine who developed haemolytic uraemic syndrome.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-010-0520-x